| Home : AbbVie Announces New Data from its Dermatology Portfolio and Pipeline at the 28th European Academy of Dermatology and Venereology (EADV) Congress |
|
Oct 09
2019 |
AbbVie Announces New Data from its Dermatology Portfolio and Pipeline at the 28th European Academy of Dermatology and Venereology (EADV) Congress |
|
NORTH CHICAGO, Ill., Oct. 9, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that it will present new results evaluating the safety and efficacy of SKYRIZI™ (risankizumab) at 2.5 years in adult patients with moderate to severe... |
|
|
|
| Source:https://www.prnewswire.com:443/news-releases/abbvie-announces-new-data-from-its-dermatology-portfolio-and-pipeline-at-the-28th-european-academy-of-dermatology-and-venereology-eadv-congress-300934529.html |
| |
|
Related News
|
» Over 200 people sign letter criticizing DC bill to decriminalize commercial sex work
» Targovax Selected for Oral Presentation at Society for Immunotherapy of Cancer (SITC) 2019 Annual Meeting
|
